Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1991-12-9
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0028-2766
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
171-2
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1944740-Administration, Oral,
pubmed-meshheading:1944740-Calcitriol,
pubmed-meshheading:1944740-Humans,
pubmed-meshheading:1944740-Hyperparathyroidism, Secondary,
pubmed-meshheading:1944740-Hyperplasia,
pubmed-meshheading:1944740-Parathyroid Glands,
pubmed-meshheading:1944740-Renal Dialysis
|
pubmed:year |
1991
|
pubmed:articleTitle |
Can oral 1,25(OH)2D3 pulse therapy reduce parathyroid hyperplasia?
|
pubmed:publicationType |
Letter
|